Work

Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for Non-Hodgkin Lymphoma

Year: 2022

Type: article

Abstract: Chimeric antigen receptor T-cell therapy (CAR-T) is a novel class of therapeutics with expanding indications. Currently, CAR-T is FDA approved for relapsed, refractory B-cell acute lymphoblastic leukemia, various subtypes of non-Hodgkin lymphoma (NHL), and multiple myeloma [ 1 ].

Source: Blood Cancer Journal

DOI: 10.1038/s41408-022-00707-4

Authors: Hassan B. Alkhateeb, Razan Mohty, Patricia Greipp, Radhika Bansal, Matthew Hathcock, Allison Rosenthal, Hemant Murthy, Mohamed Kharfan-Dabaja, Jose C. Bisneto Villasboas, Nora Bennani, Stephen M. Ansell, Mrinal M. Patnaik, Mark R. Litzow, Rong He, Dong Chen, Aref Al-Kali, Saad S. Kenderian, Yi Lin, Mithun Vinod Shah

Institutions: Mayo Clinic, Mayo Clinic in Florida, Mayo Clinic in Arizona

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $4,590

Funders: Fraternal Order of Eagles, National Cancer Institute

Award: Paul Calabresi Program in Clinical/Translational Research at Mayo Clinic

OpenAlex ID: W4288046589

FWCI: 4.249

Cites: 14

Cited by: 50

Related to: 10